# Study to Assess the Efficacy and Safety of Liraglutide in the Treatment of Type 2 Diabetes

> **NCT04373967** · PHASE3 · UNKNOWN · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 424 (estimated)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** Victoza®.
- **DRUG:** Metformin Hydrochloride
- **DRUG:** TQZ2451

## Key facts

- **NCT ID:** NCT04373967
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-04-29
- **Primary completion:** 2021-12-01
- **Final completion:** 2021-12-02
- **Target enrollment:** 424 (ESTIMATED)
- **Last updated:** 2020-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04373967

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04373967, "Study to Assess the Efficacy and Safety of Liraglutide in the Treatment of Type 2 Diabetes". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04373967. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*